BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Elotuzumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Elotuzumab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05560399-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elotuzumab: Phase 1 readout est. (NCT05560399)
DESCRIPTION:Elotuzumab\, phase 1\, Multiple Myeloma.\nStudy: A Study of Ibe
 rdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Rela
 psed/Refractory Multiple Myeloma\nEstimated primary completion: November 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/elotuzumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05560399
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elotuzumab: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Elotuzumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to D
 etermine the Recommended Dose and Regimen and to Evaluate the Safety and P
 reliminary Efficacy of CC-92480 in Combination With Standard Treatments in
  Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newl
 y Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elotuzumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT039
 89414
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02718833-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elotuzumab: Phase 2 readout est. (NCT02718833)
DESCRIPTION:Elotuzumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Elo
 tuzumab With Pomalidomide\, Bortezomib\, and Dexamethasone in Relapsed Mul
 tiple Myeloma\nEstimated primary completion: December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02718833
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981209-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elotuzumab: Phase 1 readout est. (NCT05981209)
DESCRIPTION:Elotuzumab\, phase 1\, Multiple Myeloma.\nStudy: Elotuzumab\, C
 C-92480\, and Dexamethasone for the Treatment of Relapsed or Refractory My
 eloma After CD38- and BCMA-Targeted Therapies\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 elotuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05981209
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Elotuzumab: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Elotuzumab\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor an
 d Backbone Treatments of Multiple Myeloma Patients\nEstimated primary comp
 letion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 lotuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02343042
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04835129-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Elotuzumab: Phase 2 readout est. (NCT04835129)
DESCRIPTION:Elotuzumab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, P
 omalidomide\, Elotuzumab and Dexamethasone in Relapsed and/or Refractory M
 ultiple Myeloma\nEstimated primary completion: 1 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04835129
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02420860-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Elotuzumab: Phase 2 readout est. (NCT02420860)
DESCRIPTION:Elotuzumab\, phase 2\, Multiple Myeloma.\nStudy: Elotuzumab and
  Lenalidomide After Stem Cell Transplant in Treating Patients With Newly D
 iagnosed Multiple Myeloma\nEstimated primary completion: 30 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/elotuzumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT02420860
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Elotuzumab: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Elotuzumab\, phase 3\, Multiple Myeloma.\nStudy: Study Assessin
 g Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Avail
 able Therapies in Adult Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04517851-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Elotuzumab: Phase 2 readout est. (NCT04517851)
DESCRIPTION:Elotuzumab\, phase 2.\nStudy: Elotuzumab for the Treatment of J
 AK2-Mutated Myelofibrosis\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elotuzumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04517851
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03948035-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Elotuzumab: Phase 3 readout est. (NCT03948035)
DESCRIPTION:Elotuzumab\, phase 3\, Multiple Myeloma.\nStudy: Elotuzumab in 
 Combination With Carfilzomib\, Lenalidomide and Dexamethasone (E-KRd) Vers
 us KRd in MM\nEstimated primary completion: August 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03948035
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06518551-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Elotuzumab: Phase 1 readout est. (NCT06518551)
DESCRIPTION:Elotuzumab\, phase 1\, Multiple Myeloma.\nStudy: ELEVATE-MM: El
 otuzumab\, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Rel
 apsed and Refractory Multiple Myeloma\nEstimated primary completion: 31 De
 cember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elotuzum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6518551
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06785415-3132@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20310401
DTEND;VALUE=DATE:20310402
SUMMARY:Elotuzumab: Phase 1/2 readout est. (NCT06785415)
DESCRIPTION:Elotuzumab\, phase 1/2\, Multiple Myeloma.\nStudy: Elotuzumab\,
  Daratumumab\, Iberdomide\, and Dexamethasone for the Treatment of Relapse
 d Multiple Myeloma\nEstimated primary completion: 1 April 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06785415
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
